Evolution of randomized controlled trials in adult neurosurgical critical care from 1990 to 2024 in the United States
In brief
Just six of 27 neurosurgical ICU trials showed significant benefit
A review of phase III randomized trials from 1990-2024 involving 28,291 adult neuro-critical care patients found that only six studies (22%) demonstrated a clear advantage for the tested intervention. Most trials used medical therapies, focused on mortality scales, and rarely included quality-of-life outcomes, underscoring the need for more patient-centered research.
- Journal
- Neurosurgical review (Q1)
- Published
- 14 July 2026
- Study design
- Narrative review / expert opinion
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Tristen McGee James, Mohamed-Yahia Monawar, Eric Shaker, Aden P Haskell-Mendoza, Ariel Gonzalez, Pakawat Chongsathidkiet, et al.
- PMID
- 42443603
- DOI
- 10.1007/s10143-026-04389-5
Why clinicians should know about it
- Picked for Neurosurgery (top studies of the week, 19 July 2026): Narrative review of RCT evolution, not primary evidence
Abstract
Randomized controlled trials (RCTs) are the gold standard for clinical care. Acute conditions such as traumatic brain injury, intracerebral hemorrhage, aneurysmal subarachnoid hemorrhage, and spinal cord injury are associated with high morbidity and mortality, yet guidelines are based on limited Class I evidence. This study aimed to examine the design, funding, outcomes, and reporting quality of phase III RCTs in neurosurgical critical care published since 1990. MEDLINE and Cochrane Central were searched for phase III RCTs published since January 1, 1990, with at least one arm in the U.S. and published in selected high-impact journals. Eligible studies included adult patients with common critical care neurosurgical pathologies evaluating interventions with clinically relevant outcomes. Two reviewers independently screened and extracted data with adjudication by a third. Analyses included χ² tests, ANOVA or Kruskal-Wallis tests, and linear regression. Among 586 records screened, 27 phase III RCTs (28,291 patients) met inclusion criteria. Most evaluated medical therapies; only three (11%) assessing surgical interventions. Six trials (22%) demonstrated significant benefit. The modified Rankin Scale or Glasgow Coma Scale were primary endpoints in 74% of studies. Quality-of-life measures were included in 37% but never showed significant improvement. Industry funding (33%) was not associated with positive outcomes (P = .62). Modern CONSORT fulfillment was observed in 22%, improving over time (P = .02). Phase III RCTs in neurosurgical critical care are limited, highlighting the need for greater emphasis on patient-centered outcomes and transparency in future research.Clinical trial number: Not applicable.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.